Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13382296 | 0.81 | KDM4E (0.55) | KDM4ELMNAALDH1A1HPGDCYP1A2 | |
| SCHEMBL18990911 | 0.79 | NPSR1 (0.48) | KDM4ELMNAALDH1A1HPGDCYP1A2 | |
| SCHEMBL11625985 | 0.76 | KDM4E (0.51) | KDM4ELMNAALDH1A1HPGDCYP1A2 | |
| SCHEMBL18137696 | 0.75 | KDM5B (0.50) | KDM4ELMNAALDH1A1CYP1A2MAPT | |
| SCHEMBL16346557 | 0.74 | KDM4E (0.49) | KDM4ELMNAALDH1A1HPGDCYP1A2 | |
| SCHEMBL21410580 | 0.73 | KDM4E (0.45) | KDM4ELMNAALDH1A1HPGDMAPT | |
| SCHEMBL18137689 | 0.72 | KDM5B (0.48) | KDM4ELMNAALDH1A1CYP1A2MAPT | |
| SCHEMBL21410839 | 0.71 | KDM4E (0.43) | KDM4ELMNAALDH1A1HPGDCYP1A2 | |
| SCHEMBL23611731 | 0.70 | BRD4 (0.49) | KDM4EALDH1A1CYP1A2MAPTHTT | |
| SCHEMBL2126222 | 0.70 | ALDH1A1 (0.44) | KDM4ELMNAALDH1A1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109897011-B | IDO inhibitor and application thereof | 上海华汇拓医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | BLADE THERAPEUTICS INC (US) | 2022-11-03 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220104496-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2022-04-07 | — | — | US | disclosed |
| US-11229208-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | SYNGENTA PARTICIPATIONS AG (CH) | 2022-01-25 | — | — | US | disclosed |
| US-11229208-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | SYNGENTA PARTICIPATIONS AG (CH) | 2022-01-25 | — | — | US | disclosed |
| EP-3820864-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | Blade Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-112703188-A | Method for treating liver fibrosis using calpain inhibitor | 布莱德治疗公司 | 2021-04-23 | — | — | CN | disclosed |
| US-10939682-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | SYNGENTA PARTICIPATIONS AG (CH) | 2021-03-09 | — | — | US | disclosed |
| US-10939682-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | SYNGENTA PARTICIPATIONS AG (CH) | 2021-03-09 | — | — | US | disclosed |
| WO-2015000715-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2015-01-08 | — | — | WO | disclosed |
| CN-103497148-A | Hydroxylamine compounds and methods of their use | OTHERA HOLDING INC | 2014-01-08 | — | — | CN | disclosed |
| EP-2620429-A1 | Hydroxylamine compounds and methods of their use | Colby Pharmaceutical Company (US) | 2013-07-31 | — | — | EP | disclosed |
| CN-101687786-B | Hydroxylamine compounds and methods of use thereof | OTHERA HOLDING INC | 2013-05-22 | — | — | CN | disclosed |
| EP-2125716-A2 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | Othera Holding, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-2120942-A2 | DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE | Othera Holding, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080280890-A1 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | COLBY PHARMACEUTICAL COMPANY | 2008-11-13 | — | — | US | disclosed |
| WO-2008103613-A2 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | OTHERA HOLDING, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101195-A2 | DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE | OTHERA HOLDING, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | COLBY PHARMACEUTICAL COMPANY | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220104496-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | GSTA1, CYP1B1, DDT | KDM4E 3562/4885LMNA 2366/4885ALDH1A1 149/4885 |
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | CAPNS1, CAPN9, CAPN2 | KDM4E 2666/4885LMNA 829/4885ALDH1A1 2718/4885 |
| US-10939682-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | DDT, TST, SCLY | KDM4E 3403/4885LMNA 4668/4885ALDH1A1 2859/4885 |
| US-11229208-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | GSTA1, CYP1B1, DDT | KDM4E 3562/4885LMNA 2366/4885ALDH1A1 149/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | KDM4E 3495/4885LMNA 1415/4885ALDH1A1 4193/4885 |
| US-20080280890-A1 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | HDGF, HMOX1, HMOX2 | KDM4E 4017/4885LMNA 1875/4885ALDH1A1 161/4885 |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | VHL, ABCC1, SLC11A2 | KDM4E 1383/4885LMNA 1465/4885ALDH1A1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.